Pharmacokinetics and tolerability of bosentan in patients with mild liver impairment.

被引：0
|
作者：
van Giersbergen, P [1 ]
Popescu, G [1 ]
Dingamanse, J [1 ]
机构：
[1] Actelion Pharmaceut Ltd, APEX Res, Allschwil, Switzerland
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2003年 / 73卷 / 02期
关键词：
D O I：
10.1016/S0009-9236(03)90665-5
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P84 / P84
页数：1
相关论文
共 50 条
  • [31] Vitamin E and donepezil for the treatment of mild cognitive impairment.
    Marder K.
    Current Neurology and Neuroscience Reports, 2005, 5 (5) : 337 - 338
  • [32] SINGLE-DOSE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF THE DUAL ENDOTHELIN RECEPTOR ANTAGONIST APROCITENTAN IN SUBJECTS WITH MODERATE HEPATIC IMPAIRMENT.
    Fontes, M.
    Halabi, A.
    Tomaszewska-Kiecana, M.
    Dinge-Manse, J.
    Sidharta, P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S47 - S48
  • [33] Pharmacokinetics and safety following a single oral dose of niraparib in patients with moderate hepatic impairment.
    Akce, Mehmet
    El-Khoueiry, Anthony B.
    Piha-Paul, Sarina Anne
    Bacque, Emeline
    Pan, Peng
    Zhang, Zhi-Yi
    Ewesuedo, Reginald
    Gupta, Divya
    Milton, Ashley
    Judson, Patricia
    O'Bryant, Cindy L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] Correlation between depressive symptom severity and functional status in patients with mild cognitive impairment.
    Won, Wangyoun
    INTERNATIONAL PSYCHOGERIATRICS, 2023, 35 : 228 - 229
  • [35] Pharmacokinetics, Efficacy and SAFETY of Lesinurad, a Novel URAT1 Inhibitor, In Individuals with Mild to Moderate Renal Impairment.
    Hagerty, David
    Kerr, Brad
    Shen, Zangong
    Yeh, Li-tain
    Hingorani, Vijay
    Cravets, Matt
    Welp, Jody
    Miner, Jeffrey N.
    Manhard, Kimberly
    Quart, Barry
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S402 - S402
  • [36] Electrocortical networks in Parkinson's disease patients with Mild Cognitive Impairment. The PaCoS study
    Mostile, Giovanni
    Giuliano, Loretta
    Monastero, Roberto
    Luca, Antonina
    Cicero, Calogero Edoardo
    Donzuso, Giulia
    Dibilio, Valeria
    Baschi, Roberta
    Terranova, Roberta
    Restivo, Vincenzo
    Sofia, Vito
    Zappia, Mario
    Nicoletti, Alessandra
    PARKINSONISM & RELATED DISORDERS, 2019, 64 : 156 - 162
  • [37] Mild Behavioral Impairment. Assessment, biological and clinical factors in the cognitive impairment continuum
    Juncos-Rabadan, Onesimo
    INTERNATIONAL PSYCHOGERIATRICS, 2023, 35 : 24 - 25
  • [38] Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients
    Christopher Poole
    Jill Gardiner
    Chris Twelves
    Patrick Johnston
    Peter Harper
    Jim Cassidy
    Jayne Monkhouse
    Ludger Banken
    Erhard Weidekamm
    Bruno Reigner
    Cancer Chemotherapy and Pharmacology, 2002, 49 : 225 - 234
  • [39] Pharmacokinetics, safety, and tolerability of faldaprevir in patients with different levels of renal impairment
    Huang, Fenglei
    Moschetti, Viktoria
    Lang, Benjamin
    Halabi, Atef
    Petersen-Sylla, Marc
    Yong, Chan-Loi
    Elgadi, Mabrouk
    HEPATOLOGY, 2013, 58 : 431A - 432A
  • [40] Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients
    Poole, C
    Gardiner, J
    Twelves, C
    Johnston, P
    Harper, P
    Cassidy, J
    Monkhouse, J
    Banken, L
    Weidekamm, E
    Reigner, B
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2002, 49 (03) : 225 - 234
12345